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Following brain injury, reactive glial cells can create scars that inhibit neural repair responses. In this issue of
Cell Stem Cell, Guo et al. report that overexpression of NeuroD1 in vivo can directly reprogram reactive glial
cells into glutamatergic and GABAergic neurons that integrate into the host’s neural circuitry.Glial cells, including astrocytes and oligo-
dendrocytes, support a wide range of
brain functions, such as synaptic forma-
tion/pruning, transmission and mainte-
nance of the blood-brain barrier, and
growth and myelination of axons. During
injury and neurodegenerative diseases,
astrocytes respond to damage by prolif-
erating and undergoing hypertrophy,
with increased expression of the inter-
mediate filament glial fibrillary acidic pro-
tein (GFAP), resulting in the formation
of compact glial scars. This response is
supplemented by NG2 cells, resident
progenitors that give rise mostly to oligo-
dendrocytes, which participate in gliosis
in addition to regenerating cells lost to
injury. Gliotic scars are generally inhibitory
to neuronal survival and axonal regenera-
tion. In this issue of Cell Stem Cell, Guo
et al. (2014) exploit glial scars as a cellular
source for direct reprogramming into
neuronal populations.
‘‘Melting’’ glial scars has been attemp-
ted for decades with little success. Alter-
native strategies include transforming
inhibitory gliotic tissue into an environ-
ment conducive to neuronal regeneration
or perhaps directly converting this tissue
into neurons. The latter idea has gained
momentum following the transformative
discovery that cells of one type could be
directly converted into another lineage
by introduction of cell-fate-determining
transcription factors (Takahashi and Ya-
manaka, 2006). Fibroblasts have been
reprogrammed to functional neurons
in vitro by overexpressing the transcrip-
tion factors Ascl1, Brn2a, and Myt1l, and
the efficiency of this direct conversion
was further enhanced by addition of
the neuronal-specific bHLH transcription
factor NeuroD1 (Pang et al., 2011; Yanget al., 2011). Cultured astrocytes have
been converted to neurons with even
simpler combinations of transcription
factors, such asNeuroG2 and Ascl1, likely
due to the common neuroectodermal
origin of these cell types (Berninger
et al., 2007). What remains to be deter-
mined is if reactive glia can be converted
to neurons in the environment of an
injured or diseased brain and whether
these reprogrammed neurons are func-
tional in situ.
In this issue ofCell Stem Cell, Guo et al.
(2014) show that they are able to convert
reactive (proliferating) astrocytes and
NG2 glia to functional neurons by retro-
viral expression of a single transcription
factor, NeuroD1, in both injury and
Alzheimer’s disease models. The authors
first utilized a stab-wound mouse model
of brain injury, which elicits an acute
gliotic response. Following injection
of retrovirus expressing NeuroD1 into
cortical areas of the stab-wounded brain,
without penetrating the hippocampus
or subventricular zone (to avoid targeting
neural progenitors), they show that in-
fected cells convert into neurons as early
as 3 days after viral infection. Importantly,
by whole-cell patch-clamping in brain
slices, they demonstrate that the con-
verted neurons are not only electrophy-
siologically active but that they also
integrate into neural circuitry, as shown
by spontaneous and evoked synaptic
currents. This phenomenon was then
replicated in a mouse model of Alz-
heimer’s disease (5XFAD mice), in which
chronic and progressive gliosis takes
place. Interestingly, in this model, the
authors found that more new neurons
were formed following infection with
NeuroD1 retrovirus in later stages ofCell Stem Cell 14disease, likely because of increasing
numbers of proliferating reactive glia dur-
ing disease progression. Together, the
authors demonstrate convincingly that
reactive glia in injured and diseased
mouse brains can be converted to func-
tional neurons by NeuroD1 overexpres-
sion (Figure 1). Previously, in vivo reprog-
ramming of astrocytes into neuroblasts
via Sox2 overexpression in the adult
brain has been reported (Niu et al.,
2013). In contrast to the findings of Guo
et al., cells infected with Sox2 could
potentially give raise to many neural cell
types, including converted neuroblasts,
and further differentiation to functional
neurons appears to require additional
signals (Niu et al., 2013).
Neurons converted directly from fibro-
blasts and astrocytes by panneural tran-
scription factors, including NeuroD1,
have been shown to be largely glutama-
tergic, though GABAergic neurons are
also observed in vitro (Berninger et al.,
2007; Pang et al., 2011; Vierbuchen
et al., 2010). In the current study, the
authors observed that GABAergic neu-
rons were formed even though the
majority of converted neurons were gluta-
matergic. To determine whether these
neurons with distinct neurotransmitter
phenotypes arose from NeuroD1-medi-
ated conversion of different populations
of reactive glial cells, the authors em-
ployed cell-type-specific promoters to
drive NeuroD1 expression specifically
in either astrocytes (using a GFAP pro-
moter) or NG2 cells (using an NG2 pro-
moter). In this set of experiments, they
found that astrocytes are induced exclu-
sively to glutaminergic neurons whereas
NG2 cells are reprogrammed to either
glutaminergic or GABAergic neurons by, February 6, 2014 ª2014 Elsevier Inc. 133
Figure 1. Direct Conversion of Reactive Glial Cells to Active Neurons
via NeuroD1 Expression
Cortical reactive astrocytes and NG2 glial cells in stab-wound and Alzheimer’s
disease (5XFAD) mouse models are directly converted to electrophysiologi-
cally active neurons by retroviral delivery of NeuroD1 in vivo. Astrocytes are
capable of becoming glutaminergic neurons whereas NG2 glial cells are
capable of converting into both glutaminergic and GABAergic neurons. Image
adapted from Chouchane and Costa (2012).
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finding is quite interesting
because it suggests that
NeuroD1 may interact with
other cell-type-specific tran-
scription factors to determine
the transmitter phenotype of
converted neurons. Neuronal
phenotypes, including neu-
rotransmitter identities, are
often determined by region-
specific expression of HLH
transcription factors within
their respective progenitor
populations in the developing
brain. Similarly, glial subtype
specification is also impacted
by homeodomain transcrip-
tion factors. It would be
of great interest, with signifi-
cant value for future appli-
cations, to determine the
roles that glial subtypes or
their transcriptional codes
play in shaping the func-
tional phenotypes of reprog-
rammed neurons.
The authors then asked
whether human glia could besimilarly converted to functional neurons
using this approach. To address this
question, the authors used the same
GFAP::NeuroD1 viral system to infect
cultured fetal human cortical astrocytes
and found that human astrocytes could
likewise be efficiently reprogrammed
into functional glutaminergic, but not
GABAergic, neurons. This is similar to
previous findings showing reprogram-
ming of human nonneuronal cells to neu-
ral progenitors and functional neurons
by similar approaches (Lu et al., 2013;
Pang et al., 2011; Ring et al., 2012; Vier-
buchen et al., 2010). Therefore, conver-
sion of human glia directly to neurons is
possible in vitro.
The ability to directly convert reactive
glia into neurons in injured or diseased
brain tissue, as shown by Guo et al.134 Cell Stem Cell 14, February 6, 2014 ª201(2014), raises the possibility of modifying
inhibitory gliotic tissues for therapeutic
gains. However, there are a number of
issues that must be addressed before
moving forward with potential clinical
applications. Technically, a more effi-
cient and safer method for introducing
genetic material into patients’ cells will
be necessary for clinical translation of
these findings. More importantly, future
work is needed to demonstrate inte-
gration of converted neurons into appro-
priate neural circuits and whether this
contributes to functional improvement.
Additionally, further work to elucidate
the mechanisms of cell-type-specific
conversion into neurons with distinct
phenotypes is required. Knowledge
gained from these experiments could
in turn allow conversion of specific glial4 Elsevier Inc.populations into neuronal
subtypes for therapy in an
injury-specific or neurode-
generative-disease-specific
manner. For instance, the
ability to convert glial cells
into motor or dopaminergic
neurons in vivo could have
profound implications for
treatment of ALS and Parkin-
son’s disease, respectively.
This study by Guo et al.
lays the groundwork for
further exploration of poten-
tial regenerative therapy for
neurological injury and neuro-
degenerative diseases.
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